722
Participants
Start Date
April 30, 2010
Primary Completion Date
May 31, 2016
Study Completion Date
May 31, 2016
HyperAcute-Pancreas Immunotherapy
Up to 18 immunizations of 300 million immunotherapy cells
Gemcitabine
Gemcitabine 1000 mg/m2/day once a week for 3 weeks
5FU Chemoradiation
5FU 200-250 mg/m2/day over 5 1/2 weeks with radiation.
Mount Sinai Medical Center, New York
Columbia University, New York
University of Pittsburg Medical Center, Pittsburgh
Penn State Hershey Cancer Institute, Hershey
St. Luke's Hospital and Health Network, Bethlehem
University of Pennsylvania, Philadelphia
Thomas Jefferson University, Philadelphia
Fox Chase Cancer Center, Philadelphia
Georgetown University, Washington D.C.
University of Maryland, Baltimore
University of Virginia, Charlottesville
Virginia Commonwealth University, Richmond
Lynchburg Hematology-Oncology Clinic, Inc., Lynchburg
Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem
Duke University Medical Center, Durham
Greenville Health System, Greenville
Mayo Clinic, Jacksonville
University of Florida, Gainesville
University of Miami, Miami
Boca Raton Hospital, Boca Raton
USF Tampa General, Tampa
MOFFITT, Tampa
Lakeland Regional Cancer Center, Lakeland
University of Alabama, Birmingham
University of South Alabama, Mobile
University of Louisville, Louisville
Ohio State University, Columbus
University Hospitals Case Western, Cleveland
University of Cincinnati, Cincinnati
Indiana University, Indianapolis
Investigative Clinical Research of Indiana, LLC, Indianapolis
Indiana University Health Goshen Center for Cancer Care, Goshen
Beaumont Hospital, Royal Oak
University of Michigan, Ann Arbor
Henry Ford Hospital, Detroit
University of Iowa, Iowa City
University of Wisconsin, Madison
Vince Lombardi Cancer Clinic, Green Bay
Virginia Piper Cancer Institute, Minneapolis
Mayo Clinic, Rochester
Illinois Cancer Specialists, Arlington Heights
Edward H. Kaplan, MD and Associates, Skokie
Northshore University Health Systems, Evanston
Northwestern University, Chicago
Washington University, St Louis
University of Missouri, Columbia
University of Kansas Cancer Center, Westwood
University of Nebraska Medical Center, Omaha
Ochsner Cancer Institute, New Orleans
Mary Bird Perkins Cancer Center, Baton Rouge
University of Arkansas for Medical Sciences, Little Rock
University of Oklahoma, Oklahoma City
University of Texas Southwestern Medical Center, Dallas
Baylor College of Medicine, Houston
Ben Taub Hospital, Houston
The Methodist Hospital, Houston
University of Texas Health Sciences, San Antonio
Joe Arrington Cancer Research and Treatment Center, Lubbock
University of Colorado, Aurora
Arizona Cancer Center, Tucson
University of New Mexico, Albuquerque
University of Southern California, Los Angeles
Cedars-Sinai Medical Center, Los Angeles
City of Hope National Medical Center, Duarte
California Pacific Medical Center, San Francisco
Stanford Cancer Center, Palo Alto
Sutter Institute for Medical Research, Sacramento
Oregon Health and Science University, Portland
University of Washington- Seattle Cancer Center Alliance, Seattle
Stamford Hospital, Stamford
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Lahey Clinic, Burlington
Roger Williams Medical Center, Providence
Lead Sponsor
NewLink Genetics Corporation
INDUSTRY